Overview

Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected Subjects

Status:
Unknown status
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of Raltegravir and Epzicom over 48 weeks in ART-naive HIV-infected subjects.
Phase:
Phase 4
Details
Lead Sponsor:
Denver Infectious Disease Consultants, PLLC
Collaborator:
GlaxoSmithKline
Treatments:
Abacavir
Dideoxynucleosides
Lamivudine
Raltegravir Potassium